Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
0.9348
-0.0042 (-0.45%)
At close: Sep 5, 2025, 4:00 PM
0.9311
-0.0037 (-0.40%)
After-hours: Sep 5, 2025, 7:55 PM EDT
Aditxt Employees
Aditxt had 26 employees as of December 31, 2024. The number of employees decreased by 21 or -44.68% compared to the previous year.
Employees
26
Change (1Y)
-21
Growth (1Y)
-44.68%
Revenue / Employee
$464
Profits / Employee
-$1,193,895
Market Cap
4.65M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26 | -21 | -44.68% |
| Dec 31, 2023 | 47 | -14 | -22.95% |
| Dec 31, 2022 | 61 | 3 | 5.17% |
| Dec 31, 2021 | 58 | 15 | 34.88% |
| Dec 31, 2020 | 43 | 41 | 2,050.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ADTX News
- 12 days ago - Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030 - Business Wire
- 16 days ago - Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law - PRNewsWire
- 18 days ago - FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis - PRNewsWire
- 23 days ago - Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update - PRNewsWire
- 26 days ago - Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative - Business Wire
- 4 weeks ago - Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference - PRNewsWire
- 5 weeks ago - Aditxt's Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases - Business Wire
- 6 weeks ago - Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test - Business Wire